Autophagy is increased along with ERK phosphorylation when gastric cancer cells are treated with a proteasome inhibitor [55], therefore mutations in ULK1 may affect sensitivity to proteasomal inhibitor treatments such as bortezomib as a single agent or in combination with MEK inhibitors. Here, MAP2K7 is linked to gastric cancer.